Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alaunos TherapeuticsTCRT 29 EV-to-OCF is -1.41 as of Aug. 09, 2026. GuruFocus rates TCRT with a GF Score™ of 29/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,407 Biotechnology companies, Alaunos Therapeutics ranks worse than 62.05% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Alaunos Therapeutics's Enterprise Value is $4.41 Mil.
Alaunos Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.13 Mil. Therefore, Alaunos Therapeutics's EV-to-OCF for today is -1.41.
The historical rank and industry rank for Alaunos Therapeutics's EV-to-OCF or its related term are showing as below:
TCRT'
s EV-to-OCF Range Over the Past 10 Years
Min: -66.62 Med: -6.2 Max: -0.03
Current: -1.41
During the past 13 years, the highest EV-to-OCF of Alaunos Therapeutics was -0.03. The lowest was -66.62. And the median was -6.20.
TCRT's EV-to-OCF is ranked worse than 62.05% of 1407
companies
in the Biotechnology industry
Industry Median: -3.45
vs TCRT: -1.41
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alaunos Therapeutics's PE Ratio (TTM) for today is calculated as:
Alaunos Therapeutics's share price for today is $1.95.
Alaunos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.130.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Alaunos Therapeutics EV-to-OCF Related Terms
Alaunos Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Alaunos Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Alaunos Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alaunos Therapeutics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alaunos Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Alaunos Therapeutics's EV-to-OCF falls into.
Alaunos Therapeutics's current Enterprise Value is $4.41 Mil.
Alaunos Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alaunos Therapeutics (TCRT) has a EV-to-OCF of -1.41 as of Aug. 09, 2026. According to the industry distribution chart, Alaunos Therapeutics ranks #873 out of 1407 companies in the Biotechnology industry, placing it in the top 62%.
Is Alaunos Therapeutics' EV-to-OCF too high?
Alaunos Therapeutics' current EV-to-OCF is -1.41. Based on the distribution chart, Alaunos Therapeutics ranks #873 out of 1407 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alaunos Therapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alaunos Therapeutics' EV-to-OCF compare to JAGX and LABT?
According to the Biotechnology industry distribution chart, Alaunos Therapeutics ranks #873 out of 1407 companies for EV-to-OCF. This places Alaunos Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Alaunos Therapeutics's current EV-to-OCF is -1.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alaunos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $1.95 — trading 186.8% above its estimated fair value. The current EV-to-OCF is -1.41. Alaunos Therapeutics' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current EV-to-OCF is -1.41 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alaunos Therapeutics (TCRT) Overvalued in 2026?
Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued.
The current stock price of $1.95 is trading 186.8% above its estimated GF Value™ of $0.68.
GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.
Key valuation signals for TCRT:
EV-to-OCF: -1.41
GF Value™: $0.68 vs. price of $1.95 (186.8% above fair value)
No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
29GF Score
Get the complete analysis for TCRT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCRT has been successfully added to your 
